Effect of linezolid on the 50% lethal dose and 50% protective dose in treatment of infections by gram-negative pathogens in naive and immunosuppressed mice and on the efficacy of ciprofloxacin in an acute murine model of septicemia

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4671-4675

  Marra, Andrea ^a,b   Lamb, Lucinda ^a,c   Medina, Ivette ^a,d   George, David ^a   Gibson, Glenn ^a,e   Hardink, Joel ^a   Rugg, Jady ^a   Van Deusen, Jeffrey ^a   O'Donnell, John P ^a,f  

^a PFIZER INC   (United States)

^b Rib X Pharmaceuticals   (United States)

^c HARTFORD HOSPITAL   (United States)

^d Hartford Hospital ^*  (United States)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; LINEZOLID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GRAM NEGATIVE INFECTION; KLEBSIELLA PNEUMONIAE; LD 50; LUNG INFECTION; MONOTHERAPY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPTICEMIA; SURVIVAL;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; IMMUNOCOMPROMISED HOST; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LETHAL DOSE 50; MICE; MODELS, ANIMAL; OXAZOLIDINONES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84865408007     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00276-12     Document Type: Article

References (23)

1. Bayer Healthcare. 2008. Cipro® (ciprofloxacin hydrochloride) tablets, Cipro® (ciprofloxacin) oral suspension. Revised October 2008. http://www.univgraph.com/bayer/inserts/ciprotab.pdf.
2. Brickner SJ. 1996. Oxazolidinone antibacterial agents. Curr. Pharm. Des. 2:175-194. (Pubitemid 126474511)
3. CLSI. 2010. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. CLSI document M100-S20. CLSI, Wayne, PA.
4. Diekema DJ, Jones RN. 2001. Oxazolidinone antibiotics. Lancet 358:1975-1982. (Pubitemid 34072884)
5. Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. 2011. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob. Agents Chemother. 55:3684-3690.
6. Hanna D, et al. 2009. Pharmacokinetic/pharmacodynamic (PK/PD) analysis of linezolid (LZD) in combination with aztreonam (ATM) and ceftazidime (CAZ) against E. coli: use of in vitro PK models to assess combinations at therapeutically relevant drug concentrations, abstr A1-547. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
7. Höffken G, Lode H, Prinzing C, Borner K, Koeppe P. 1985. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob. Agents Chemother. 27:375-379. (Pubitemid 15144703)
8. Hosaka M, et al. 1992. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob. Agents Chemother. 36:2108-2117.
9. Hsieh MH, Yu CM, Yu VL, Chow JW. 1993. Synergy assessed by checkerboard. A critical analysis. Diagn. Microbiol. Infect. Dis. 16:343-349. (Pubitemid 23146839)
10. Jones RN, Stilwell MG, Hogan PA, Sheehan DJ. 2007. Activity of linezolid tested against uncommonly isolated gram-positive organisms (3,251 strains): report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 51:1491-1493. (Pubitemid 46586834)
11. LaPlante KL, Sakoulas G. 2009. Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 53:4549-4555.
12. Liu XG, Li RC. 2001. Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. J. Chemother. 13:563-568. (Pubitemid 33001121)
13. MacGowan AP. 2003. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother. 51(Suppl 2):ii17-25. (Pubitemid 36622108)
14. Mortin LI, et al. 2007. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob. Agents Chemother. 51:1787-1794. (Pubitemid 46744159)
15. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1. (Pubitemid 36850074)
16. Pfizer. 2012. Zyvox® (linezolid) injection, (linezolid tablets, (linezolid) for oral suspension. Pfizer LAB-0139-21.0, revised February 2012. http://labeling.pfizer.com/ShowLabeling.aspx?id=649.
17. Sisson TL, Jungbluth GL, Hopkins NK. 1999. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J. Clin. Pharmacol. 39:1277-1282. (Pubitemid 30644009)
18. Slatter JG, et al. 2002. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 32:907-924. (Pubitemid 35155524)
19. Stalker DJ, Jungbluth GL. 2003. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin. Pharmacokinet. 42:1129-1140. (Pubitemid 37357649)
20. Sweeney MT, Zurenko GE. 2003. In vitro activity of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected gram-negative organisms. Antimicrob. Agents Chemother. 47:1902-1906. (Pubitemid 36637812)
21. Thallinger C, et al. 2008. Effect of severity of sepsis on tissue concentrations of linezolid. J. Antimicrob. Chemother. 61:173-176.
22. Wilcox MH, et al. 2009. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin. Infect. Dis. 48:203-212.
23. Yanagihara K, et al. 2002. Efficacy of linezolid against methicillinresistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection. Antimicrob. Agents Chemother. 46:3288-3291.